ABT-737 is a BH3 mimetic that acts as an inhibitor of Bcl-2, Bxl-xl, and Bcl-ω. ABT-737 exhibits anticancer chemotherapeutic and antithrombotic activities. ABT-737 is currently in clinical trials as one component of a combination therapy in the treatment of various cancers such as acute myelogenous leukemia (AML). This compound inhibits growth of AML cells in vitro and increases survival rates and lifespan in animal models of AML. In vitro, ABT-737 induces mitochondrial membrane depolarization in platelets, inducing apoptosis and clearance.